Masaki Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masaki Kato has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Motoyuki Kohjima
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
8 shared publicationsAkifumi Kuwano
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
5 shared publicationsHideo Suzuki
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
5 shared publicationsMunechika Enjoji
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
5 shared publicationsYoshihiro Ogawa
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
5 shared publicationsKazuhiro Kotoh
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan
4 shared publications
Latest Publications
- Open Access
- 1 September 2021
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 27, 101068
Upregulated expression of hypoxia reactive genes in peripheral blood mononuclear cells from chronic liver disease patients
- 1 September 2021
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 27, 101068
Open AccessUpregulated expression of hypoxia reactive genes in peripheral blood mononuclear cells from chronic liver disease patients
- Open Access
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antivirals (DAAs). However, it remains unclear if DAAs themselves have an influence on or facilitate the development of HCC. This multicenter cohort study included CHC patients without a history of HCC who achieved HCV elimination by DAAs. Cohorts of 835 patients treated with a sofosbuvir (SOF)-based regimen and 835 treated with a SOF-free regimen were matched 1:1 by propensity scoring with nine variables to evaluate differences in HCC incidence. The median observation period was 3.5 years. Sixty-nine cases of HCC were found during 5483.9 person-years (PY) over the entire follow-up period. The annual incidence was similar for both groups (SOF-based 1.25 and SOF-free 1.27 per 100 PY, respectively: adjusted hazard ratio (HR) 1.26, 95% confidence interval (CI) 0.75–2.12, p = 0.39). However, the annual incidence within the first two years was higher for patients treated with SOF than for those without, but did not reach significance (1.50 and 0.97 per 100 PY incidence rates, respectively: adjusted HR 2.05, 95% CI 0.98–4.25, p = 0.06). In summary, DAA treatment with SOF was not associated with an increase in the development of de novo HCC.
Open AccessIncidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antivirals (DAAs). However, it remains unclear if DAAs themselves have an influence on or facilitate the development of HCC. This multicenter cohort study included CHC patients without a history of HCC who achieved HCV elimination by DAAs. Cohorts of 835 patients treated with a sofosbuvir (SOF)-based regimen and 835 treated with a SOF-free regimen were matched 1:1 by propensity scoring with nine variables to evaluate differences in HCC incidence. The median observation period was 3.5 years. Sixty-nine cases of HCC were found during 5483.9 person-years (PY) over the entire follow-up period. The annual incidence was similar for both groups (SOF-based 1.25 and SOF-free 1.27 per 100 PY, respectively: adjusted hazard ratio (HR) 1.26, 95% confidence interval (CI) 0.75–2.12, p = 0.39). However, the annual incidence within the first two years was higher for patients treated with SOF than for those without, but did not reach significance (1.50 and 0.97 per 100 PY incidence rates, respectively: adjusted HR 2.05, 95% CI 0.98–4.25, p = 0.06). In summary, DAA treatment with SOF was not associated with an increase in the development of de novo HCC.
- Open Access
- 18 December 2019
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2019, 1-12
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients
Aim. Immune checkpoint inhibitors (ICIs) have improved the survival rate of patients carrying various malignant neoplasms. Despite their efficacy, ICIs occasionally induce liver injury as an immune-related adverse event (irAE). This study aimed to reveal the clinical features of the hepatic irAE in Japanese patients. Methods. Among 387 patients treated with ICIs, those who developed drug-induced liver injury were investigated. We also describe the histological findings and clinical courses of four patients with hepatic irAE who underwent liver biopsy. Results. Among the 56 patients with all-grade liver injury, only 11 (19.6%) showed hepatocellular-type liver injury, which resembled autoimmune hepatitis. Thirty-four patients (60.7%) developed cholestatic or mixed-type liver injury, although only one patient showed abnormal image findings in the bile duct. Most patients with grade ≤2 liver injury improved spontaneously, while two patients with biliary dysfunction required ursodeoxycholic acid or prednisolone. Among eight patients with grade ≥3 liver injury, three required no immunosuppressants and five were treated with prednisolone (three of five patients required other types of immunosuppressants). Four patients in the case series showed diverse clinical features in terms of hepatotoxic pattern, symptoms, and the interval time between the initiation of immunotherapy and the onset of the hepatic irAE. Conclusions. Our findings suggest that ICIs could cause microscopic biliary disorder without any abnormal image finding. Because the hepatic irAE presents diverse clinical features, liver biopsy is recommended to provide appropriate treatments.
- 18 December 2019
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2019, 1-12
Open AccessClinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients
Aim. Immune checkpoint inhibitors (ICIs) have improved the survival rate of patients carrying various malignant neoplasms. Despite their efficacy, ICIs occasionally induce liver injury as an immune-related adverse event (irAE). This study aimed to reveal the clinical features of the hepatic irAE in Japanese patients. Methods. Among 387 patients treated with ICIs, those who developed drug-induced liver injury were investigated. We also describe the histological findings and clinical courses of four patients with hepatic irAE who underwent liver biopsy. Results. Among the 56 patients with all-grade liver injury, only 11 (19.6%) showed hepatocellular-type liver injury, which resembled autoimmune hepatitis. Thirty-four patients (60.7%) developed cholestatic or mixed-type liver injury, although only one patient showed abnormal image findings in the bile duct. Most patients with grade ≤2 liver injury improved spontaneously, while two patients with biliary dysfunction required ursodeoxycholic acid or prednisolone. Among eight patients with grade ≥3 liver injury, three required no immunosuppressants and five were treated with prednisolone (three of five patients required other types of immunosuppressants). Four patients in the case series showed diverse clinical features in terms of hepatotoxic pattern, symptoms, and the interval time between the initiation of immunotherapy and the onset of the hepatic irAE. Conclusions. Our findings suggest that ICIs could cause microscopic biliary disorder without any abnormal image finding. Because the hepatic irAE presents diverse clinical features, liver biopsy is recommended to provide appropriate treatments.
- Open Access
- 11 June 2019
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 18 (2) , 1323-1330
Recombinant human soluble thrombomodulin ameliorates acetaminophen‑induced liver toxicity in mice
Recombinant human soluble thrombomodulin alpha (rhTM) has been developed as an anticoagulant with anti‑inflammatory activity. Notably, acetaminophen (APAP) ‑induced liver disease (AILI) is caused by direct metabolite‑induced hepatotoxicity as well as hepatic hyper‑coagulation. To evaluate the utility of anticoagulant for the treatment of AILI, rhTM was administered in a mouse AILI model and liver damage was analyzed. AILI was induced in 8‑week‑old mice by intraperitoneal injection of APAP. rhTM (20 mg/kg) or placebo was injected at the same time as APAP administration. Serum alanine aminotransferase, fibrin degradation products and high‑mobility group box 1 levels were significantly decreased in the rhTM‑treated group compared with the control group. Furthermore, rhTM reduced the necrotic area and fibrin deposition in liver sections. rhTM suppressed the mRNA expression of heme oxygenase‑1, plasminogen activator inhibitor type‑1, tissue factors, and inflammatory cytokines compared with the control group. rhTM did not change the hepatic GSH content at 2 h after APAP injection, but restored them at 4 h after the insult. rhTM ameliorated liver damage in mice with AILI, probably via the improvement in liver perfusion induced by it's anticoagulant acitivity, which can lead to the suppression of secondary liver damage.
- 11 June 2019
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 18 (2) , 1323-1330
Open AccessRecombinant human soluble thrombomodulin ameliorates acetaminophen‑induced liver toxicity in mice
Recombinant human soluble thrombomodulin alpha (rhTM) has been developed as an anticoagulant with anti‑inflammatory activity. Notably, acetaminophen (APAP) ‑induced liver disease (AILI) is caused by direct metabolite‑induced hepatotoxicity as well as hepatic hyper‑coagulation. To evaluate the utility of anticoagulant for the treatment of AILI, rhTM was administered in a mouse AILI model and liver damage was analyzed. AILI was induced in 8‑week‑old mice by intraperitoneal injection of APAP. rhTM (20 mg/kg) or placebo was injected at the same time as APAP administration. Serum alanine aminotransferase, fibrin degradation products and high‑mobility group box 1 levels were significantly decreased in the rhTM‑treated group compared with the control group. Furthermore, rhTM reduced the necrotic area and fibrin deposition in liver sections. rhTM suppressed the mRNA expression of heme oxygenase‑1, plasminogen activator inhibitor type‑1, tissue factors, and inflammatory cytokines compared with the control group. rhTM did not change the hepatic GSH content at 2 h after APAP injection, but restored them at 4 h after the insult. rhTM ameliorated liver damage in mice with AILI, probably via the improvement in liver perfusion induced by it's anticoagulant acitivity, which can lead to the suppression of secondary liver damage.
- Open Access
- 20 March 2019
- Published by Japan Society of Hepatology in Kanzo
- Vol. 60 (3) , 91-98
Successful endoscopic treatment of hepatoduodenal fistula formed during sorafenib treatment for hepatocellular carcinoma with duodenal invasion
症例は79歳女性.肝細胞癌術後およびC型肝硬変SVR後で当院通院中であった.2017年10月黒色便を主訴に受診し,精査の結果肝細胞癌の再発とその十二指腸浸潤部からの腫瘍出血と診断された.浸潤部からの出血は自然止血した.動脈塞栓術や外科的治療の適応は乏しいと判断され,ソラフェニブ400 mg/dayを開始した.2018年1月に腹部CTおよび上部消化管内視鏡検査では,再発癌部は縮小し十二指腸浸潤部には肝十二指腸瘻が出現していた.瘻孔閉鎖のためポリグリコール酸シートとフィブリン糊による内視鏡的瘻孔閉鎖処置を行い,さらに瘻孔周囲をアルゴンプラズマ凝固にて焼灼した.瘻孔は縮小傾向を示しソラフェニブ治療を継続したところ,同年5月には瘻孔は閉鎖した.十二指腸浸潤を伴う肝細胞癌の縮小とともに生じた肝十二指腸瘻を,内視鏡的に閉鎖しえた症例を経験したので報告する.
- 20 March 2019
- Published by Japan Society of Hepatology in Kanzo
- Vol. 60 (3) , 91-98
Open AccessSuccessful endoscopic treatment of hepatoduodenal fistula formed during sorafenib treatment for hepatocellular carcinoma with duodenal invasion
症例は79歳女性.肝細胞癌術後およびC型肝硬変SVR後で当院通院中であった.2017年10月黒色便を主訴に受診し,精査の結果肝細胞癌の再発とその十二指腸浸潤部からの腫瘍出血と診断された.浸潤部からの出血は自然止血した.動脈塞栓術や外科的治療の適応は乏しいと判断され,ソラフェニブ400 mg/dayを開始した.2018年1月に腹部CTおよび上部消化管内視鏡検査では,再発癌部は縮小し十二指腸浸潤部には肝十二指腸瘻が出現していた.瘻孔閉鎖のためポリグリコール酸シートとフィブリン糊による内視鏡的瘻孔閉鎖処置を行い,さらに瘻孔周囲をアルゴンプラズマ凝固にて焼灼した.瘻孔は縮小傾向を示しソラフェニブ治療を継続したところ,同年5月には瘻孔は閉鎖した.十二指腸浸潤を伴う肝細胞癌の縮小とともに生じた肝十二指腸瘻を,内視鏡的に閉鎖しえた症例を経験したので報告する.
- 1 August 2018
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 118, 190-197
Effects of high fructose intake on liver injury progression in high fat diet induced fatty liver disease in ovariectomized female mice
- 1 August 2018
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 118, 190-197
Effects of high fructose intake on liver injury progression in high fat diet induced fatty liver disease in ovariectomized female mice
- Open Access
- 9 August 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (6) , 1077-1081
Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is considered a hepatic manifestation of metabolic syndrome, which is known to be associated with insulin resistance (IR). NAFLD occurs when the rate of hepatic fatty acid uptake from plasma and de novo fatty acid synthesis is greater than the rate of fatty acid oxidation and excretion as very low-density lipoprotein (VLDL). To estimate the effects of IR on hepatic lipid excretion, mRNA expression levels of genes involved in VLDL assembly were analyzed in NAFLD liver. Twenty-two histologically proven NAFLD patients and 10 healthy control subjects were enrolled in this study. mRNA was extracted from liver biopsy samples and real-time PCR was performed to quantify the expression levels of apolipoprotein B (apoB), microsomal triglyceride transfer protein (MTP) and liver fatty-acid binding protein (L-FABP). Hepatic expression levels of the genes were compared between NAFLD patients and control subjects. In NAFLD patients, we also examined correlations between expression levels of the genes and metabolic factors, including IR, and the extent of obesity and hepatic lipid accumulation. Hepatic expression levels of apoB, MTP and L-FABP were significantly up-regulated in NAFLD patients compared to control subjects. The expression levels of MTP were correlated with those of apoB, but not with those of L-FABP. In the NAFLD liver, the expression levels of MTP were significantly reduced in patients with HOMA-IR >2.5. In addition, a significant reduction in MTP expression was observed in livers with advanced steatosis. Enhanced expression of genes involved in VLDL assembly may be promoted to release excess lipid from NAFLD livers. However, the progression of IR and hepatic steatosis may attenuate this compensatory process.
- 9 August 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (6) , 1077-1081
Open AccessEffects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is considered a hepatic manifestation of metabolic syndrome, which is known to be associated with insulin resistance (IR). NAFLD occurs when the rate of hepatic fatty acid uptake from plasma and de novo fatty acid synthesis is greater than the rate of fatty acid oxidation and excretion as very low-density lipoprotein (VLDL). To estimate the effects of IR on hepatic lipid excretion, mRNA expression levels of genes involved in VLDL assembly were analyzed in NAFLD liver. Twenty-two histologically proven NAFLD patients and 10 healthy control subjects were enrolled in this study. mRNA was extracted from liver biopsy samples and real-time PCR was performed to quantify the expression levels of apolipoprotein B (apoB), microsomal triglyceride transfer protein (MTP) and liver fatty-acid binding protein (L-FABP). Hepatic expression levels of the genes were compared between NAFLD patients and control subjects. In NAFLD patients, we also examined correlations between expression levels of the genes and metabolic factors, including IR, and the extent of obesity and hepatic lipid accumulation. Hepatic expression levels of apoB, MTP and L-FABP were significantly up-regulated in NAFLD patients compared to control subjects. The expression levels of MTP were correlated with those of apoB, but not with those of L-FABP. In the NAFLD liver, the expression levels of MTP were significantly reduced in patients with HOMA-IR >2.5. In addition, a significant reduction in MTP expression was observed in livers with advanced steatosis. Enhanced expression of genes involved in VLDL assembly may be promoted to release excess lipid from NAFLD livers. However, the progression of IR and hepatic steatosis may attenuate this compensatory process.
- Open Access
- 19 January 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (2) , 195-199
Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure
Although the mechanism involved in acute liver failure (ALF) has not yet been clarified, microcirculatory disturbance in the liver appears to play a pivotal role in the progression of this disease. To confirm the existence of hepatic hypoxic conditions, we evaluated the amounts of lactate dehydrogenase (LDH) in hepatocytes, since its production increases under low oxygen concentrations. Histological examination was performed in 7 patients with ALF. All 7 patients underwent a liver biopsy during the acute phase of ALF, and 4 of them underwent a second biopsy during the recovery phase. The obtained samples were immunohistochemically stained with anti-LDH5 and anti-CD-68 antibodies. As controls, we examined samples from patients with acute hepatitis, chronic hepatitis and liver cirrhosis. The production of LDH by hepatocytes and the number of CD-68 positive macrophages were markedly increased at the acute phase of ALF, and both of these effects abruptly decreased during the recovery phase. By contrast, most of the samples from the patients with chronic hepatitis and acute hepatitis showed slightly any increase in LDH staining. In cirrhotic patients, partially elevated LDH production was observed mainly around the central vein, but the staining intensity was less compared to that in ALF patients. Our findings indicate that hepatic hypoxic conditions exist in ALF at the acute phase and seem to closely correlate with macrophage overactivation in the liver. We speculate that microcirculatory disturbance may be a key process in the development and progression of ALF.
- 19 January 2011
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 2 (2) , 195-199
Open AccessLactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure
Although the mechanism involved in acute liver failure (ALF) has not yet been clarified, microcirculatory disturbance in the liver appears to play a pivotal role in the progression of this disease. To confirm the existence of hepatic hypoxic conditions, we evaluated the amounts of lactate dehydrogenase (LDH) in hepatocytes, since its production increases under low oxygen concentrations. Histological examination was performed in 7 patients with ALF. All 7 patients underwent a liver biopsy during the acute phase of ALF, and 4 of them underwent a second biopsy during the recovery phase. The obtained samples were immunohistochemically stained with anti-LDH5 and anti-CD-68 antibodies. As controls, we examined samples from patients with acute hepatitis, chronic hepatitis and liver cirrhosis. The production of LDH by hepatocytes and the number of CD-68 positive macrophages were markedly increased at the acute phase of ALF, and both of these effects abruptly decreased during the recovery phase. By contrast, most of the samples from the patients with chronic hepatitis and acute hepatitis showed slightly any increase in LDH staining. In cirrhotic patients, partially elevated LDH production was observed mainly around the central vein, but the staining intensity was less compared to that in ALF patients. Our findings indicate that hepatic hypoxic conditions exist in ALF at the acute phase and seem to closely correlate with macrophage overactivation in the liver. We speculate that microcirculatory disturbance may be a key process in the development and progression of ALF.
- 1 January 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (1) , 30-38
Potential role of branched‐chain amino acids in glucose metabolism through the accelerated induction of the glucose‐sensing apparatus in the liver
Branched‐chain amino acids (BCAAs) have a potential to improve glucose metabolism in cirrhotic patients; however, the contribution of liver in this process has not been clarified. To estimate the effect of BCAA on glucose metabolism in liver, we evaluated the mRNA expression levels of glucose‐sensing apparatus genes in HepG2 cells and in rat liver after oral administration of BCAA. HepG2 cells were cultured in low glucose (100 mg/dl) or high glucose (400 mg/dl) in the absence or presence of BCAA. The mRNA expression levels and protein levels of GLUT2 and liver‐type glucokinase (L‐GK) were estimated using RT‐PCR and immunoblotting. The expression levels of transcriptional factors, including SREBP‐1c, ChREBP, PPAR‐γm and LXRα, were estimated. The mRNA expression levels of transcriptional factors, glycogen synthase, and genes involved in gluconeogenesis were evaluated in rat liver at 3 h after the administration of BCAA. BCAA accelerated the expression of GLUT2 and L‐GK in HepG2 cells in high glucose. Expression levels of ChREBP, SREBP‐1c, and LXRα were also increased in this condition. BCAA administration enhanced the mRNA expression levels of L‐GK, SREBP‐1c, and LXRα and suppressed the expression levels of G‐6‐Pase in rat liver, without affecting the expression levels of glycogen synthase or serum glucose concentrations. BCAA administration enhanced the bioactivity of the glucose‐sensing apparatus, probably via the activation of a transcriptional mechanism, suggesting that these amino acids may improve glucose metabolism through the accelerated utility of glucose and glucose‐6‐phosphate in the liver. J. Cell. Biochem. 112: 30–38, 2011.
- 1 January 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (1) , 30-38
Potential role of branched‐chain amino acids in glucose metabolism through the accelerated induction of the glucose‐sensing apparatus in the liver
Branched‐chain amino acids (BCAAs) have a potential to improve glucose metabolism in cirrhotic patients; however, the contribution of liver in this process has not been clarified. To estimate the effect of BCAA on glucose metabolism in liver, we evaluated the mRNA expression levels of glucose‐sensing apparatus genes in HepG2 cells and in rat liver after oral administration of BCAA. HepG2 cells were cultured in low glucose (100 mg/dl) or high glucose (400 mg/dl) in the absence or presence of BCAA. The mRNA expression levels and protein levels of GLUT2 and liver‐type glucokinase (L‐GK) were estimated using RT‐PCR and immunoblotting. The expression levels of transcriptional factors, including SREBP‐1c, ChREBP, PPAR‐γm and LXRα, were estimated. The mRNA expression levels of transcriptional factors, glycogen synthase, and genes involved in gluconeogenesis were evaluated in rat liver at 3 h after the administration of BCAA. BCAA accelerated the expression of GLUT2 and L‐GK in HepG2 cells in high glucose. Expression levels of ChREBP, SREBP‐1c, and LXRα were also increased in this condition. BCAA administration enhanced the mRNA expression levels of L‐GK, SREBP‐1c, and LXRα and suppressed the expression levels of G‐6‐Pase in rat liver, without affecting the expression levels of glycogen synthase or serum glucose concentrations. BCAA administration enhanced the bioactivity of the glucose‐sensing apparatus, probably via the activation of a transcriptional mechanism, suggesting that these amino acids may improve glucose metabolism through the accelerated utility of glucose and glucose‐6‐phosphate in the liver. J. Cell. Biochem. 112: 30–38, 2011.
- Open Access
- 1 January 2010
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 9 (1) , 29
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1 inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to ezetimibe. In each patient, body mass index was maintained under 25 kg/m2 during the observation period. Serum ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (<30 U/L), which was accompanied with at least a 10% decrease in serum total cholesterol and LDL-cholesterol. However, ultrasonographic findings of fatty liver did not show obvious improvement for a year. We conclude that the cholesterol absorption inhibitor ezetimibe can suppress hepatic injury in non-obese patients with NAFLD and that ezetimibe may offer a novel treatment for NAFLD.
- 1 January 2010
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 9 (1) , 29
Open AccessNPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. We reviewed a year of follow-up data of non-obese NAFLD patients treated with Niemann-Pick C1 like 1 inhibitor ezetimibe to evaluate its therapeutic effect on clinical parameters related to NAFLD. Without any dietary or exercise modification, 10 mg/day of ezetimibe was given to 8 patients. In 4 of 8 patients, ezetimibe was administered initially. In the remaining 4 patients, medication was switched from ursodeoxycholic acid to ezetimibe. In each patient, body mass index was maintained under 25 kg/m2 during the observation period. Serum ALT levels significantly decreased within 6 months and in 4 patients levels reached the normal range (<30 U/L), which was accompanied with at least a 10% decrease in serum total cholesterol and LDL-cholesterol. However, ultrasonographic findings of fatty liver did not show obvious improvement for a year. We conclude that the cholesterol absorption inhibitor ezetimibe can suppress hepatic injury in non-obese patients with NAFLD and that ezetimibe may offer a novel treatment for NAFLD.